GALNT14 Genotyping for HCC Chemotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy options for advanced hepatocellular carcinoma (HCC) are ineffective, with single-agent chemotherapies showing low response rates and significant side effects, and combination regimens offering limited survival benefits and high variability in patient responses, making it challenging to select a suitable treatment.
Innovation Solution
The method involves determining the GALNT14 gene genotype, specifically the rs9679162 polymorphism, to predict responsiveness to a 5-FU-based combination chemotherapy, which includes 5-FU, mitoxantrone, and cisplatin, using specific primers and restriction enzymes to amplify and analyze the target nucleic acid, thereby identifying suitable patients for this treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination chemotherapy regimens are used to treat advanced HCC, then response rate is improved, but side effects increase and survival benefit remains limited
Solution Approach 1:
The patent applies preliminary action by determining the GALNT14 genotype before chemotherapy treatment to predict patient responsiveness. This pre-treatment genetic assessment allows clinicians to identify patients likely to respond to 5-FU-based combination chemotherapy, thereby avoiding unnecessary treatment exposure for non-responders and reducing overall side effects while maintaining high response rates in selected patients
2Productivity
If combination chemotherapy is administered to all HCC patients, then more patients receive potential treatment benefit, but variability in individual response increases and treatment effectiveness decreases
Solution Approach 1:
The patent applies local quality by tailoring chemotherapy treatment to individual patient genotypes. Specifically, patients with certain GALNT14 genotypes are selected for 5-FU-based combination chemotherapy, while other patients receive alternative treatments. This personalized approach ensures that each patient receives the most effective treatment for their specific genetic profile, maximizing treatment effectiveness while maintaining broad treatment coverage
3Reliability
If genotype-based patient selection is implemented, then treatment effectiveness is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies mechanics substitution by replacing complex clinical judgment and trial-and-error treatment selection with a straightforward genetic test. The GALNT14 genotype determination provides an objective, binary classification (responsive vs. non-responsive) that simplifies the diagnostic process. This molecular marker-based approach substitutes complex multifactorial assessment with a single, clear genetic test result, making genotype-based selection clinically feasible
Data Source
AI summary
Disclosed herein is a method for identifying single nucleotide polymorphisms of a target nucleic acid for predicting whether a patient suffering from hepatocellular carcinoma will respond to a 5-fluorouracil (5-FU)-based combination chemotherapy. In some embodiments, biological sample derived from the patient is processed to determine the presence of a T/T genotype of rs9679162 GALNT14 gene. The presence of the above-identified genotype is an indication that the patient is responsive to the 5-FU-based combination chemotherapy.